Roche secures EU approval for wider use of lung cancer drug

04/29/2010 | Reuters

Roche Holding said European regulators approved Tarceva as a maintenance treatment for advanced nonsmall-cell lung cancer. The drug received FDA approval earlier this month for this indication. Roche also said its Type 2 diabetes treatment taspoglutide yielded positive results in a late-stage trial.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY